Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study
BACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of EMDCT including therapy receiving cases with ceftazidime/avibactam (CAZAVI) receiving CRKPI cases. MATERIALS/METHODS: This study was performed at a 1800+ bedded tertiary-care educational universi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524001851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | BACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of EMDCT including therapy receiving cases with ceftazidime/avibactam (CAZAVI) receiving CRKPI cases. MATERIALS/METHODS: This study was performed at a 1800+ bedded tertiary-care educational university hospital. Adult (>18 years old) patients with culture proven CRKPI (bacteremia, pneumonia, urinary tract infections (UTI), intraabdominal infections (IAI)) treated with EMDCT or CAZAVI including regimens between August 2016 and October 2023 were included in the study. Matching was performed as one CAZAVI matched to minimum 1 or 2 EMDCT when n is possible according to the sample infecting strain was yielded (bacteremia vs. bacteremia etc.) Blood cultures were performed on Bact-Alert (Bio Merioux, France). Antimicrobial susceptibility tests were performed via VITEK 2 system (bioMérieux). Resistance to carbapenems was tested by E-test (bioMérieux). The results were interpreted according to the EUCAST criteria. RESULTS: A total of 69 patients(25 female, aged 63,14±13,74), 42 cases in EMDCT group and 27 cases in cef-avi group diagnosed with CRKPN bacteremia (18 cases), pneumonia (24 cases), UTI(18 cases), IAI (9 cases) were included in the study. Age, gender, duration of therapy, all cause day 30 mortality in the overall cohort, bacteremia, UTI, pneumonia subgroups, end of treatment clinical and microbiological response, relapse and reinfection in one mont post-treatment follow up rates did not differ significantly between two cohorts (Table-1). CONCLUSIONS: Although the number of cases is relatively low and non-randomized, CAZAVI and EMDCT containing therapy resulted in quiet similar outcome in our matched cohort study. |
|---|---|
| ISSN: | 2213-7165 |